| |
Normal urothelium without HCV
|
Normal urothelium with HCV
|
Malignant urothelium without HCV
|
Malignant urothelium with HCV
|
|---|
|
Telomerase :
|
|
• hTERT by RT-PCR
|
0.13 ± 0.05
|
2.37 ± 0.44a
|
6.16 ± 0.57 ab
|
11.88 ±1.34 abc
|
|
• hTERT by IH (+ve cases)
|
3 (6%)
|
12 (24%)
|
24 (48%)
|
38 (76%)
|
|
Mean labeled cells
|
11.53 ± 2.82
|
14.90 ± 1.46
|
31.65 ± 9.02
|
44.36 ± 9.84
|
|
TRAP (ng/ml)
|
0.54 ± 0.24
|
2.98 ± 0.59 a
|
8.03 ± 1.26 ab
|
15.88 ± 1.94 abc
|
|
(positive cases)
|
2 (4%)
|
10 (20%)
|
32 (64%)
|
41 (82)
|
|
Tumour suppressor genes:
|
|
• Rb by RT-PCR
|
11.27 ± 1.42
|
6.92 ± 0.81 a
|
2.75 ± 0.65 ab
|
0.32 ± 0.30 abc
|
|
• Rb by IH ( positive cases)
|
3 (6%)
|
12 (24%)
|
26 (52%)
|
40 (80%)
|
|
• E2F3 by RT-PCR
|
0.41 ±0.09
|
1.74 ± 0.47 a
|
3.60 ±1.22 ab
|
9.75 ± 4.32 abc
|
|
• TP53 by RT-PCR
|
0.25 ± 0.34
|
1.68 ± 0.29 a
|
3.92 ± 0.46 ab
|
12.39 ± 1.82 abc
|
|
• p53 by IH (positive cases)
|
0 (0%)
|
3 (6%)
|
21 (42%)
|
42 (84)
|
|
• P21 by RT-PCR
|
9.80 ± 0.45
|
5.83 ± 0.86 a
|
3.19 ± 0.45 ab
|
0.25 ±0.34 abc
|
|
• P21 by IH ( positive cases)
|
49 (98%)
|
31 (62%)
|
13 (26%)
|
3 (6%)
|
|
Protooncogenes:
|
|
• FGFR3 by RT-PCR
|
0.08 ± 0.12
|
0.86 ± 0.76
|
3.06 ± 2.45 ab
|
2.87 ± 3.88 ab
|
|
• FGFR3 by IH (positive cases)
|
0 (0%)
|
2 (4%)
|
38 (76%)
|
48 (96%)
|
- All data are expressed as Mean ± SD. One way ANOVA test with posthoc Scheffe’s test. a significant vs normal urothelium without HCV, b significant vs normal urothelium with HCV, C significant vs malignant urothelium without HCV (p< 0.05).
